Eyenovia raises ~$2.0M in registered direct offering at $0.6204/share

HYPERION DEFI, INC.

Sold 3,223,726 shares at $0.6204/share to a single healthcare investor; gross proceeds ~$2.0M.
Net proceeds to fund commercialization of Mydcombi and clobetasol propionate, complete CHAPERONE study.
Offering expected to close on or about April 11, 2024, subject to customary conditions.
Shares issued under existing effective shelf registration statement (No. 333-261638).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

HYPERION DEFI, INC. entered into Purchase Agreement with a single fundamentals-based healthcare investor valued at approximately $2.0 million (effective 2024-04-08).

Action: entry
Agreement: equity purchase
Counterparty: a single fundamentals-based healthcare investor
Value: approximately $2.0 million
Effective: 2024-04-08

Exact text from the filing

On April 8, 2024, Eyenovia, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with a single fundamentals-based healthcare investor (the “Purchaser”)

View on SEC.gov

419 material agreements filed in the last 30 days. Browse all material agreements →

HYPERION DEFI, INC. filing history →

Source: SEC EDGAR

accession 0001104659-24-045015

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.